NSAID-induced ulcerative ileocolitis;Ulzerierende ileokolitis unter NSAR-therapie

Medizinische Klinik

Volumn 96, Issue 3, 2001, Pages 166-170

  Bächle, Thomas ^a   Dreher, Ulrich ^a   Rühl, Udo ^b   Walker, Siegfried ^a   Erbel, Raimund ^a  

^a KLINIKUM LUDWIGSBURG   (Germany)

^b Klinikum   (Germany)

Author keywords

Diarrhea; Ileocolitis; NSAID

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; SERUM ALBUMIN;

ABDOMINAL PAIN; AGED; ANEMIA; ARTICLE; CASE REPORT; COLONOSCOPY; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DRUG INDUCED DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MUSCLE WEAKNESS; ULCERATIVE COLITIS; WEIGHT REDUCTION;

POMACANTHUS MACULOSUS; SIGMOIDEA;

EID: 0035868610     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002189     Document Type: Article

References (41)

1. Sulfasalazine reduces indomethacin induced changes in small intestinal permeability in man
2. Intestinal permeability and inflammation in rheumatoid arthritis; effects of nonsteroidal anti-inflammatory drugs
3. Blood and protein loss via small intestinal inflammation induced by non-steroidal antiinflammatory drugs
4. Misoprostol reduces indomethacin induced changes in human small intestinal permeability
5. Metronidazole reduces inflammation and blood loss in NSAID enteropathy
6. Nonsteroidal antiinflammatory drug-induced intestinal inflammation in humans
7. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans
8. COX-2 specific inhibition with MK-0966 25 or 50 mg qd does not increase intestinal permeability: A controlled study with placebo and indomethacin 50 mg tid
9. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: A case-control study
10. Salicylate-induced exacerbation of ulcerative colitis
11. The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal antiinflammatory drugs
12. Relevance of intestinal bacteria, prostaglandins, and pro-drug administration to NSAID induced increase in gut permeability
13. Pharmalogical protection of NSAID-induced intestinal permeability in the rat: Effect of tempo and metronidazole as potential free radical savengers
14. Intestinal perforation associated with slow release indomethacin capsules
15. Indomethacin-induced intestinal inflammation
16. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthrits or osteoarthritis, and interim report on prevention by misoprostol of diclofenac associated lesions
17. Die Nebenwirkungen nicht-steroidaler antirheumatika im unteren Gastrointestinaltrakt
18. Nichtsteroidale antirheumatika und azetylsalizylsäure: Nebenwirkungen distal des duodenums
19. COX-2 specific inhibition with MK-0966 or 50 mg qd over 4 weeks does not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg tid
20. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group
21. Use of anti-inflammatory drugs by patients with small or large bowel perforation and haemorrhage
22. Solitary rectal lesions due to suppositories containing acetylsalicylic acid and paracetamol
23. Selective inhibition of cyclooxygenase-2 (COX-2) with MK-0966 (250 mg qd) is associated with less gastroduodenal damge than aspirin (ASA) 650 mg qid or ibuprofen (IBU) 800 mg tid
24. Nil nocere. Arzneimittelbedingte Dünndarmulcera
25. Selective COX-2 Inhibitors and human inflammatory powel disease
26. A comparison of indomethacin with ibuprofen on gastrointestinal mucosal integrity in conventional and germ free rats
27. Study of the molecular mechanism of decreased synthesis of albumin in inflammation
28. Gastrointestinal perforation following indomethacin therapy in very low birthweight infants
29. Analgesic ingestion and other factors preceeding relapse in ulcerative colitis
30. Nonsteroidal antiinflammatory drug enteropathy in rats: Role of permeability, bacteria and enteropathic circulation
31. Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release
32. Role of bacteria in gastric ulceration produced by indomethacin in the rat: Cytoprotective action of antibiotics
33. Enterocyte mitochondrial damage due to NSAID in the rat
34. The biochemical basis of nonsteroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: A review and a hypothesis
35. Mitochondrial damage: A possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine
36. Colonic inflammation and NSAID administration
37. Intestinal inflammation and bleeding in NSAID enteropathy and inflammatory bowel disease
38. High prevalence of NSAID enteropathy as shown by a simple fecal test
39. Non steroidal anti-inflammatory drug gastropathy and cytoprotection: Pathogenesis and mechanisms re-examinend
40. Complications of diverticular disease and nonsteroidal anti-inflammatory-drugs: A prospective study